MetaCap

Canton Strategic (CNTN) vs Unicycive Therapeutics (UNCY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Unicycive Therapeutics (UNCY) has outperformed Canton Strategic (CNTN) over the past year, losing 38.0% versus a loss of 50.6%. Canton Strategic is the larger company by market cap ($98.8 million vs $97.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTN-50.61%UNCY-37.96%
+132%+37%-59%
Nov 21, 20251 yearNov 20, 2026
CNTN-99.89%UNCY-81.28%
+57%-25%-107%
Jan 10, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTN versus UNCY key metrics
MetricCNTNUNCY
Share price$1.21$3.35
Market cap$98.78M$97.77M
1-day change-1.63%-5.10%
YTD return-60.07%-41.94%
1-year return-50.61%-37.96%
5-year return—-88.53%
P/E ratio (TTM)20.17—
Forward P/E—4.86
EPS (TTM)$0.06$-1.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-35.92M$-26.55M
52-week high$5.83$8.74
52-week low$1.19$3.33
Distance from 52-week high-79.25%-61.67%
Analyst consensus—strong_buy
Avg. price target upside—+685.07%
Average volume763.63K963.80K
Shares outstanding81.64M29.18M
Employees1221
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • UNCY has outperformed CNTN by 12.6 percentage points over the past year.

About Canton Strategic

CNTN stock →

Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Unicycive Therapeutics

UNCY stock →

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

CNTN vs UNCY FAQ

Which is bigger, Canton Strategic or Unicycive Therapeutics?

Canton Strategic (CNTN) is larger, with a market capitalization of $98.78M compared with $97.77M for Unicycive Therapeutics (UNCY).

Which stock has performed better over the past year, CNTN or UNCY?

UNCY returned -37.96% over the past 12 months, compared with -50.61% for CNTN (price return, excluding dividends). Past performance does not predict future results.

Are Canton Strategic and Unicycive Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons